Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
Authors
Keywords
-
Journal
Current Atherosclerosis Reports
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-23
DOI
10.1007/s11883-020-0823-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
- (2019) Koutaro Yokote et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Efficacy and Safety of Pemafibrate in Patients with Type 2 Diabetes and Elevated Triglyceride levels: 52-Week Data From The PROVIDE Study
- (2019) Eiichi Araki et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis
- (2019) Satoshi Ida et al. Cardiovascular Diabetology
- Biochemical and Plasma Lipids Responses to Pemafibrate in Patients with Primary Biliary Cholangitis
- (2019) Satoru Joshita et al. HEPATOLOGY RESEARCH
- The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
- (2019) Jean-Charles Fruchart et al. Cardiovascular Diabetology
- Impact of fibrates on circulating cystatin C levels: a systematic review and meta-analysis of clinical trials
- (2018) Amirhossein Sahebkar et al. ANNALS OF MEDICINE
- Effects of Selective PPARα Modulator K-877 on Particle Numbers of Lipoprotein Subclasses in Dyslipidemic Patients: Analysis by GP-HPLC and NMR Lipoprofile 2 and 3
- (2018) Shizuya Yamashita et al. ATHEROSCLEROSIS SUPPLEMENTS
- A Pooled Analysis of Pemafibrate Phase II/III Clinical Trials Indicated Significant Improvement in Glycemic and Liver Function-related Parameters
- (2018) Koutaro Yokote et al. ATHEROSCLEROSIS SUPPLEMENTS
- Pemafibrate Minimally Affected the Systemic Exposure of Statins, and Vice Versa, in Healthy Male Volunteers
- (2018) Neil Hounslow et al. ATHEROSCLEROSIS SUPPLEMENTS
- Pemafibrate Has High Bioavailability and is Principally Excreted via the Liver
- (2018) Neil Hounslow et al. ATHEROSCLEROSIS SUPPLEMENTS
- Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα
- (2018) Yuta Yamamoto et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
- (2018) Eiichi Araki et al. DIABETES CARE
- Accelerated Atherogenicity in Tangier Disease
- (2018) Jun Muratsu et al. Journal of Atherosclerosis and Thrombosis
- A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
- (2018) Masami Sairyo et al. Journal of Atherosclerosis and Thrombosis
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- Pathophysiology of Diabetic Dyslipidemia
- (2018) Tsutomu Hirano Journal of Atherosclerosis and Thrombosis
- Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia
- (2018) Shizuya Yamashita et al. Journal of Clinical Lipidology
- Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
- (2018) Shun Ishibashi et al. Journal of Clinical Lipidology
- A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
- (2018) Christophe Corpechot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
- (2018) Ikuro Matsuba et al. Journal of Diabetes Investigation
- Selective peroxisome proliferator-activated receptor-α modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells
- (2018) Tao Dong et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice
- (2018) Masaya Araki et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
- (2018) Makoto Kinoshita et al. Journal of Atherosclerosis and Thrombosis
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator, in rats and monkeys
- (2018) Shin-ichiro Ogawa et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- PPAR-α agonists are still on the rise: an update on clinical and experimental findings
- (2017) Nicola Ferri et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation
- (2017) Sadao Takahashi Journal of Atherosclerosis and Thrombosis
- Postprandial Hyperlipidemia and Remnant Lipoproteins
- (2017) Daisaku Masuda et al. Journal of Atherosclerosis and Thrombosis
- Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice
- (2017) Kenta Takei et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review
- (2017) Duminda Suraweera et al. LIVER INTERNATIONAL
- Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway
- (2017) Toshinobu Maki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
- (2017) Marshall B. Elam et al. JAMA Cardiology
- Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
- (2017) Yasushi Honda et al. Scientific Reports
- The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis
- (2016) Nathalie Hennuyer et al. ATHEROSCLEROSIS
- Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
- (2016) Shun Ishibashi et al. ATHEROSCLEROSIS
- Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
- (2016) Yaron Arbel et al. Cardiovascular Diabetology
- FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues
- (2016) Christian Schlein et al. Cell Metabolism
- Recent Advances in Analytical Methods on Lipoprotein Subclasses: Calculation of Particle Numbers from Lipid Levels by Gel Permeation HPLC Using “Spherical Particle Model”
- (2016) Mitsuyo Okazaki et al. Journal of Oleo Science
- A HIGHLY SELECTIVE PPARα AGONIST K-877 SUPPRESSES NEOINTIMA FORMATION FOLLOWING CORONARY STENTING IN SWINE
- (2016) Hiroshi Iwata et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
- (2016) Barbara Gross et al. Nature Reviews Endocrinology
- HDL Particle Size Is a Critical Determinant of ABCA1-Mediated Macrophage Cellular Cholesterol ExportNovelty and Significance
- (2015) Xian-Ming Du et al. CIRCULATION RESEARCH
- Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials
- (2015) Chi-kin Ip et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver
- (2015) Sana Raza-Iqbal et al. Journal of Atherosclerosis and Thrombosis
- The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy
- (2015) Jia Liu et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling
- (2014) A.-C. Ruwald et al. EUROPEAN HEART JOURNAL
- Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets
- (2014) Ffolliott M. Fisher et al. GASTROENTEROLOGY
- Upregulation of hepatic VLDLR via PPARα is required for the triglyceride-lowering effect of fenofibrate
- (2014) Yang Gao et al. JOURNAL OF LIPID RESEARCH
- Fibroblast growth factor 21 enhances cholesterol efflux in THP-1 macrophage-derived foam cells
- (2014) WEI SHANG et al. Molecular Medicine Reports
- HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
- (2014) Anand Rohatgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated physiology and systems biology of PPARα
- (2014) Sander Kersten Molecular Metabolism
- Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
- (2013) Jean-Charles Fruchart Cardiovascular Diabetology
- Lipoprotein metabolism and CKD: overview
- (2013) Philip Barter Clinical and Experimental Nephrology
- The clofibrate saga: a retrospective commentary
- (2012) Michael Oliver BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors
- (2012) Michel Dietz et al. ChemMedChem
- Effect of fenofibrate treatment for hyperlipidaemia on serum creatinine and cystatin C
- (2012) V. Ncube et al. ANNALS OF CLINICAL BIOCHEMISTRY
- Impaired Insulin Secretion in Four Tangier Disease Patients with ABCA1 Mutations
- (2011) Masahiro Koseki et al. Journal of Atherosclerosis and Thrombosis
- Remnant Lipoproteins As Strong Key Particles to Atherogenesis
- (2011) Yoshio Fujioka et al. Journal of Atherosclerosis and Thrombosis
- Peroxisome proliferator-activated receptor-α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis
- (2011) Claire Z Larter et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans
- (2011) Leigh Perreault et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
- (2011) Amit V. Khera et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
- (2010) Min Jun et al. LANCET
- PPARα: an emerging therapeutic target in diabetic microvascular damage
- (2010) Anne Hiukka et al. Nature Reviews Endocrinology
- Combination Lipid Therapy in Type 2 Diabetes
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease
- (2009) Jean-Charles Fruchart ATHEROSCLEROSIS
- Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-α
- (2009) Xian-sheng Huang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis
- (2009) Koji Fujita et al. HEPATOLOGY
- Myopathy with statin–fibrate combination therapy: clinical considerations
- (2009) Terry A. Jacobson Nature Reviews Endocrinology
- Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
- (2009) Bengt C. Fellström et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cholesterol in islet dysfunction and type 2 diabetes
- (2008) Liam R. Brunham et al. JOURNAL OF CLINICAL INVESTIGATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now